Akademska digitalna zbirka SLovenije - logo

Search results

Basic search    Expert search   

Currently you are NOT authorised to access e-resources SI consortium. For full access, REGISTER.

2 3 4 5 6
hits: 74
31.
  • Dynamic single-cell RNA seq... Dynamic single-cell RNA sequencing identifies immunotherapy persister cells following PD-1 blockade
    Sehgal, Kartik; Portell, Andrew; Ivanova, Elena V ... The Journal of clinical investigation, 01/2021, Volume: 131, Issue: 2
    Journal Article
    Peer reviewed
    Open access

    Resistance to oncogene-targeted therapies involves discrete drug-tolerant persister cells, originally discovered through in vitro assays. Whether a similar phenomenon limits efficacy of programmed ...
Full text
Available for: NUK, UL, UM, UPUK

PDF
32.
  • Safety and Efficacy of PD-1... Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients With Non–Small Cell Lung Cancer
    Ostios-Garcia, Lorena; Faig, Jennifer; Leonardi, Giulia C. ... Journal of thoracic oncology, July 2018, 2018-July, 2018-07-00, Volume: 13, Issue: 7
    Journal Article
    Peer reviewed
    Open access

    Despite widespread administration of programmed death receptor 1 (PD-1) pathway inhibitors among individuals with NSCLC, little is known about the safety and activity of these agents among human ...
Full text
Available for: GEOZS, IJS, IMTLJ, KILJ, KISLJ, NLZOH, NUK, OILJ, PNG, SAZU, SBCE, SBJE, UILJ, UL, UM, UPCLJ, UPUK, ZAGLJ, ZRSKP

PDF
33.
  • Effect of performance statu... Effect of performance status on survival with pembrolizumab monotherapy in advanced non-small cell lung cancer (NSCLC)
    Sehgal, Kartik; Bindal, Poorva; Koshy, Anita Geevarghese ... Journal of clinical oncology, 05/2020, Volume: 38, Issue: 15_suppl
    Journal Article
    Peer reviewed

    Abstract only 9533 Background: Pembrolizumab (P) is now widely used as standard of care (SOC) in advanced NSCLC. We sought to identify prognostic factors influencing survival with it in a real-world ...
Full text
Available for: NUK, UL, UM, UPUK
34.
  • Comparison of outcomes with... Comparison of outcomes with pembrolizumab monotherapy (P) versus combination with chemotherapy (P+C) in advanced non-small cell lung cancer (NSCLC)
    Sehgal, Kartik; Gill, Ritu R.; Bindal, Poorva ... Journal of clinical oncology, 05/2020, Volume: 38, Issue: 15_suppl
    Journal Article
    Peer reviewed

    Abstract only e21579 Background: P and P+C are standard-of-care (SOC) treatment options for advanced NSCLC. However, they have not yet been directly compared in clinical trials. Methods: We conducted ...
Full text
35.
  • Additional Oncogenic Altera... Additional Oncogenic Alterations in RAS-Driven Differentiated Thyroid Cancers Associate with Worse Clinicopathologic Outcomes
    Bikas, Athanasios; Ahmadi, Sara; Pappa, Theodora ... Clinical cancer research, 07/2023, Volume: 29, Issue: 14
    Journal Article
    Peer reviewed

    RAS mutations occur across the spectrum of thyroid neoplasms, and more tools are needed for better prognostication. The objective of this study was to evaluate how additional genetic events affecting ...
Full text
Available for: CMK, NUK, UL, UM, UPUK
36.
  • Association of Performance ... Association of Performance Status With Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy
    Sehgal, Kartik; Gill, Ritu R; Widick, Page ... JAMA network open, 02/2021, Volume: 4, Issue: 2
    Journal Article
    Peer reviewed
    Open access

    Despite approximately 40% of patients having Eastern Cooperative Oncology Group (ECOG) performance status (PS) scores of at least 2 in the real world, most landmark clinical trials that led to the ...
Full text
Available for: CMK, NUK, UL, UM, UPUK

PDF
37.
Full text
Available for: NUK, UL, UM, UPUK

PDF
38.
  • Optimization of immune-rela... Optimization of immune-related adverse event management in a thoracic oncology clinic
    Berwick, Lexie; Rangachari, Deepa; Costa, Daniel Botelho ... Journal of clinical oncology, 10/2018, Volume: 36, Issue: 30_suppl
    Journal Article
    Peer reviewed

    Abstract only 261 Background: Improved awareness and management of immune checkpoint inhibitor (ICI) related adverse events (IRAEs) is a mandate for best practice given widespread use of ICIs in ...
Full text
39.
  • Clinical, molecular, and im... Clinical, molecular, and immunologic profiling of brain metastases (BM) in head and neck squamous cell carcinoma (HNSCC)
    Dennis, Michael J.; Pavlick, Dean; Kacew, Alec ... Journal of clinical oncology, 06/2024, Volume: 42, Issue: 16_suppl
    Journal Article
    Peer reviewed

    6036 Background: BM is a rare complication of HNSCC that carries a high rate of morbidity and poor prognosis. Clinical risk factors, molecular characteristics, and the immunogenicity of HNSCC BM are ...
Full text
40.
  • Phase 1/2 study of NGM707, ... Phase 1/2 study of NGM707, an ILT2/ILT4 dual antagonist antibody, in advanced solid tumors: Interim results from dose-escalation
    Wang, Judy S.; Sommerhalder, David; Sharma, Manish ... Journal of clinical oncology, 06/2024, Volume: 42, Issue: 16_suppl
    Journal Article
    Peer reviewed

    2582 Background: The Phase 1/2, dose escalation/expansion study evaluates NGM707, a dual anti-ILT2/ILT4 humanized monoclonal antibody, as monotherapy or in combination with pembrolizumab in patients ...
Full text
2 3 4 5 6
hits: 74

Load filters